338 Emerging insights on the association of tumor molecular phenotype with clinical benefit in metastatic colorectal cancer (mCRC) subjects treated with AB928 + modified FOLFOX-6 (mFOLFOX-6). (9th November 2020)

• Record Type: Journal Article
• Authors: Udyavar, Akshata; Cecchini, Michael; DiRenzo, Daniel; Cho, Sean; Seitz, Lisa; Zhang, Kristen; Young, Stephen; Anderson, Amy; Gerrick, Kimberline; Walters, Matthew; Gilbert, Houston; Gardner, Olivia; Quah, Cheng; Jaen, Juan; Grossman, William
• Is Part Of: Journal for immunotherapy of cancer. Volume 8(2020)Supplement 3
• Page Start: A363
• Page End: A363
• Publication Date: 2020-11-09
• Subjects: Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1136/jitc-2020-SITC2020.0338
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Background: The release of ATP from dying cancer cells in response to platinum-based chemotherapy increases extracellular adenosine, which binds to and activates A2aR and A2bR receptors to generate an immunosuppressive microenvironment. This is mediated by the activation of A2aR on intra-tumoral T and NK cells, A2aR and A2bR on tumor-infiltrating myeloid cells, and A2bR on cancer cells. 1 Importantly, expression of A2bR and CD73, an adenosine-producing enzyme, on cancer cells is upregulated by oncogenic drivers such as KRAS. 2 Consistent with this, tumors from CRC subjects express high levels of A2bR. Adenosine receptor blockade may therefore enhance the therapeutic efficacy of certain chemotherapeutic agents. AB928 is the first clinical-stage small-molecule dual adenosine receptor antagonist, targeting both A2aR and A2bR. The preliminary safety and clinical efficacy of AB928 + mFOLFOX-6 in metastatic colorectal cancer (ARC-3; NCT03720678 ) were recently described. 3 This presentation describes the preliminary identification of molecular markers that correlate with the extent of clinical benefit in this trial. Methods: A total of 35 subjects enrolled in this study: 12 (1L); 4 (2L); and 19 (3L+). Baseline and on-treatment biopsy samples were subjected to immunofluorescent staining as well as WES and RNAseq analysis. Results: Analysis of the primary CRC dataset in TCGA highlights this tumor type as having high levels of CD73, coupled with a paucity of Tissue Nonspecific Alkaline Phosphatase (TNAP), another enzyme that can produce adenosine. In our mCRC study samples, TNAP was often present, being expressed on either stroma or tumor and in a non-overlapping manner with CD73. Analysis of the expression levels of these enzymes and other proteins involved in the adenosine axis (e.g., A2bR) revealed trends that could have predictive value, particularly in late-line subjects. Correlative trends were also observed between the infiltration of lymphocytes within baseline tumor samples and the extent of clinical benefit. Based on a preliminary and ongoing analysis of baseline biopsies, a number of molecular markers may correlate with better clinical outcomes, most relevantly in late-line mCRC subjects treated with AB928 + mFOLFOX-6. These data suggest the possibility that adenosine-related markers may be helpful in future studies for selection of patients to be treated with AB928 + mFOLFOX-6 therapy. Conclusions: N/A Acknowledgements: N/A Trial Registration: NCT03720678 Ethics Approval: The study was approved by all the study site Institution's Ethics Boards, with Advarra IRB being the first, approval number SSU00070639 in USA. Consent: N/A References: Vijayan D, et al. Nat Rev Cancer . 2017;17(12):765 Udyavar A, et.al AACR Annual Meeting 2019. Cecchini M, et.al. AACR Annual Meeting 2020.